Jesús García-Mata1, Cecilio Álamo2, Javier de Castro3, Jorge Contreras4, Rafael Gálvez5, Carlos Jara6, Antonio Llombart7, Concepción Pérez8, Pedro Sánchez9, Susana Traseira10, Juan-Jesús Cruz11. 1. Medical Oncology Department, Santa María Nai Hospital, Orense, Spain. 2. Department of Pharmacology, University of Alcalá de Henares, Madrid, Spain. 3. Medical Oncology Department, La Paz Hospital, Madrid, Spain. 4. Radiotherapeutic Oncology Department, Carlos Haya Hospital, Málaga, Spain. 5. Pain Clinic and Palliative Care Unit, Virgen de las Nieves Hospital, Granada, Spain. 6. Medical Oncology Department, Alcorcón Hospital, Madrid, Spain. 7. Medical Oncology Department, Arnau de Vilanova Hospital, Valencia, Spain. 8. Pain Clinic, La Princesa Hospital, Madrid, Spain. 9. Medical Oncology Department, Specialty Hospital, Jaén, Spain. 10. Medical Department, Mundipharma Pharmaceuticals, Madrid, Spain. 11. Hospital Universitario de Salamanca-Universidad de Salamanca (USAL), Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, Spain. jjcruz@usal.es.
Abstract
PURPOSE: To monitor oncologists' perspective on cancer pain management. METHODS: An anonymized survey was conducted in two waves. First, over a convenience sample of oncologists known to be particularly concerned with the management of pain. Second, using a random sample of oncologists. RESULTS: In total, 73 and 82 oncologists participated in the first and second wave, respectively. Many oncologists reported to have good knowledge of analgesic drugs (95.9%), the mechanism of action of opioids (79.5%), and good skills to manage opioid-related bowel dysfunction (76.7%). Appropriate adjustment of background medication to manage breakthrough pain was reported by 95.5% of oncologists. Additionally, 87.7% (68.3% in the second wave, p = 0.035) of oncologists reported suitable opioid titration practices, and 90.4% reported to use co-adjuvant medications for neuropathic pain confidently. On the other hand, just 9.6% of oncologists participated in multidisciplinary pain management teams, and merely 30.3 and 27.1% reported to routinely collaborate with the Pain Clinics or involve other staff, respectively. Only 26.4% of the oncologists of the second wave gave priority to pain pathophysiology to decide therapies, and up to 75.6% reported difficulties in treating neuropathic pain. Significantly less oncologists of the second wave (82.9 vs. 94.5%, p = 0.001) used opioid rotation routinely. CONCLUSIONS: Unlike in previous surveys, medical oncologists reported in general good knowledge and few perceived limitations and barriers for pain management. However, multi-disciplinary management and collaboration with other specialists are still uncommon. Oncologists' commitment to optimize pain management seems important to improve and maintain good practices.
PURPOSE: To monitor oncologists' perspective on cancer pain management. METHODS: An anonymized survey was conducted in two waves. First, over a convenience sample of oncologists known to be particularly concerned with the management of pain. Second, using a random sample of oncologists. RESULTS: In total, 73 and 82 oncologists participated in the first and second wave, respectively. Many oncologists reported to have good knowledge of analgesic drugs (95.9%), the mechanism of action of opioids (79.5%), and good skills to manage opioid-related bowel dysfunction (76.7%). Appropriate adjustment of background medication to manage breakthrough pain was reported by 95.5% of oncologists. Additionally, 87.7% (68.3% in the second wave, p = 0.035) of oncologists reported suitable opioid titration practices, and 90.4% reported to use co-adjuvant medications for neuropathic pain confidently. On the other hand, just 9.6% of oncologists participated in multidisciplinary pain management teams, and merely 30.3 and 27.1% reported to routinely collaborate with the Pain Clinics or involve other staff, respectively. Only 26.4% of the oncologists of the second wave gave priority to pain pathophysiology to decide therapies, and up to 75.6% reported difficulties in treating neuropathic pain. Significantly less oncologists of the second wave (82.9 vs. 94.5%, p = 0.001) used opioid rotation routinely. CONCLUSIONS: Unlike in previous surveys, medical oncologists reported in general good knowledge and few perceived limitations and barriers for pain management. However, multi-disciplinary management and collaboration with other specialists are still uncommon. Oncologists' commitment to optimize pain management seems important to improve and maintain good practices.
Entities:
Keywords:
Chronic pain; Clinical oncology; Delivery of health care; Medical education; Opioid analgesics; Surveys and questionnaires